Trial · NCT04480840
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | Placebo | 21 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events | PLN-74809 Dose Level 1 | 10 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events | PLN-74809 Dose Level 2 | 16 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events | PLN-74809 Dose Level 3 | 15 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events | PLN-74809 Dose Level 4 | 23 | Participants | ||
| Number of Participants With Serious Treatment Emergent Adverse Events | Placebo | 1 | Participants | ||
| Number of Participants With Serious Treatment Emergent Adverse Events | PLN-74809 Dose Level 1 | 1 | Participants | ||
| Number of Participants With Serious Treatment Emergent Adverse Events | PLN-74809 Dose Level 2 | 1 | Participants | ||
| Number of Participants With Serious Treatment Emergent Adverse Events | PLN-74809 Dose Level 3 | 0 | Participants | ||
| Number of Participants With Serious Treatment Emergent Adverse Events | PLN-74809 Dose Level 4 | 1 | Participants | ||
| Assessment of PLN-74809 Total Plasma Concentrations at Week 12 | PLN-74809 Placebo | 0.00 | Standard Deviation 0.00 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 12 | PLN-74809 Dose Level 1 | 638.71 | Standard Deviation 378.193 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 12 | PLN-74809 Dose Level 2 | 843.06 | Standard Deviation 474.312 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 12 | PLN-74809 Dose Level 3 | 2035.95 | Standard Deviation 1020.567 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 12 | PLN-74809 Dose Level 4 | 3667.50 | Standard Deviation 1598.067 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 24 | PLN-74809 Placebo | 0.00 | Standard Deviation 0.00 | ng/mL | |
| Assessment of PLN-74809 Total Plasma Concentrations at Week 24 | PLN-74809 Dose Level 4 | 3583.64 | Standard Deviation 1642.404 | ng/mL | |
| Assess Change From Baseline in Enhanced Liver Fibrosis (ELF) at Week 12 | Placebo | 0.42 | Standard Deviation 0.75 | Unitless | |
| Assess Change From Baseline in Enhanced Liver Fibrosis (ELF) at Week 12 | PLN-74809 Dose Level 1 | 0.16 | Standard Deviation 0.58 | Unitless | |
| Assess Change From Baseline in Enhanced Liver Fibrosis (ELF) at Week 12 | PLN-74809 Dose Level 2 | 0.19 | Standard Deviation 0.51 | Unitless |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04480840/results